Oral dolasetron mesilate (MDL 73,147EF) for the control of emesis during fractionated total-body irradiation and high-dose cyclophosphamide in patients undergoing allogeneic bone marrow transplantation

Supportive Care in Cancer

Volumn 5, Issue 3, 1997, Pages 219-222

  Fauser, A A ^a   Russ, W ^b   Bischoff, M ^a  

^a Dept Bone Marrow Transplant H ^*  (Germany)

^b Hoechst Marion Roussel Pharma AG   (Switzerland)

Author keywords

Antiemetic efficacy; High dose cyclophosphamide; Oral dolasetron mesilate; Safety; Total body irradiation

Indexed keywords

CYCLOPHOSPHAMIDE; DOLASETRON MESILATE;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER THERAPY; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HICCUP; HUMAN; HYPERSALIVATION; LEUKEMIA; LYMPHOMA; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PARESTHESIA; PHOTOPHOBIA; PRIORITY JOURNAL; RADIATION SICKNESS; VERTIGO; VOMITING; WHOLE BODY RADIATION; XEROSTOMIA;

ADMINISTRATION, ORAL; ADULT; ANTIEMETICS; ANTINEOPLASTIC AGENTS, ALKYLATING; BONE MARROW TRANSPLANTATION; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; INDOLES; MALE; NAUSEA; PILOT PROJECTS; QUINOLIZINES; TRANSPLANTATION CONDITIONING; VOMITING; WHOLE-BODY IRRADIATION;

EID: 0030996074     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005200050063     Document Type: Article

References (12)

1. 3 antagonist MDL 73147EF (dolasetron mesilate) and MDL 74156 in NG108-15 neuroblastoma x glioma cells. Eur J Pharmacol 219:9-13
2. Bosi A, Guidi S, Messori A, Saccardi R, Lombardini L, Vannuchi AM, Fanci R, Rossi-Ferrini P (1993) Ondansetron versus chlorpromazine for preventing emesis in bone marrow transplant recipients: a double-blind randomised study. J Chemother 5:191-196
3. Boxenbaum H, Gillespie T, Heck K, Hahne W (1993) Human dolasetron pharmaco-kinetics: II absorption and disposition following single-dose oral administration to normal male subjects. Biopharm Drug Dispos 14:131-141
4. Grant-Prentice H, Cunningham S, Gandhi L. Cunningham J, Collis C, Hamon MD (1995) Granisetron in the prevention of irradiation-induced emesis. Bone Marrow Transplant 15:445-448
5. 3 receptor antagonist for the prevention of radiation induced emesis during total body irradiation. Bone Marrow Transplant 7:439-441
6. Kris MG, Grunbers SM, Gralla RJ, Baltzer L, Zaretsky SA, Lifsey D, Tyson LB, Schmidt L, Hahne WF (1994) Dose ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin. J Clin Oncol 12:1045-1049
7. 3receptors. Drue Dev Res 28:87-93
8. Roberts JT, Priestman TJ (1993) A review of ondansetron in the management of radiotherapy-induced emesis. Oncology 50:173-179
9. Schwella N, Konig V, Schwerdtfeger R, Schmidt-Wolf I, Schmid H, Riess H, Siegert W (1994) Ondansetron for efficient emesis control during total body irradiation. Bone Marrow Transplant 13:169-171
10. Spitzer TR, Bryson JC, Cirenza E, Foelber R, Wallerstadt M, Stout C, Kunka R, Plagge PB, Dubois A (1994) Randomized double-blind, placebo controlled evaluation of oral ondansetron in the prevention of nausea and vomiting associated with fractionated total-body irradiation. J Clin Oncol 12:2432-2438
11. Tiley C, Powles R, Catalano J, Treleaven J, Eshelby J, Hewtson M, Tait D, Cunningham D (1992) Results of a double blind placebo controlled study of ondansetron as an antiemetic during total body irradiation in patients undergoing bone marrow transplantation. Leuk Lymphoma 7:317-321
12. Westbrook C, Glaholm J, Barratt A (1987) Vomiting associated with whole body irradiation. Clin Radiol 38:263-266